<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00333554</url>
  </required_header>
  <id_info>
    <org_study_id>NIP (IND)</org_study_id>
    <nct_id>NCT00333554</nct_id>
  </id_info>
  <brief_title>Nutritional Intervention to Prevent Diabetes</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 1 Diabetes (T1D) is an autoimmune disease. This means that the immune system (the part
      of the body which helps fight infections) mistakenly attacks and destroys the cells that
      produce insulin (islet cells found in the pancreas). As these cells are destroyed, the body's
      ability to produce insulin decreases.

      The autoimmune process is thought to be initiated by a gene-environment interaction. The
      genetics involved in the development of T1D are fairly well understood. There is a higher
      risk of developing T1D with the presence of the human leukocyte antigen (HLA) DR3 or DR4. It
      is also known that not everyone with these genes actually develops T1D. Therefore, one or
      more environmental factors are thought to contribute to the process of developing T1D.

      The consumption of the anti-inflammatory fatty acids, the omega-3 fatty acids, has decreased
      significantly in the past 100 years. At the same time a rise in the incidence of T1D,
      especially in young children has occurred. Because of the warnings to eliminate fish during
      pregnancy, pregnant women are consuming even less omega-3 fatty acids during fetal
      development.

      Observations have been made that children who have received omega-3 fatty acid
      supplementation have a lower risk of T1D. Omega-3 fatty acids could have a protective effect
      that may occur during pregnancy, infancy, or both. The mechanism of this protection may be
      due to the DHA mediated suppression of the inflammatory response.

      Patients at higher risk for T1D have an increased pro-inflammatory environment. We
      hypothesize that DHA supplementation during pregnancy and early childhood will block the
      initial pro-inflammatory events and prevent development of islet cell autoimmunity in
      children at higher risk for T1D.

      This study is a feasibility study to determine if a full-scale DHA supplementation study will
      be implemented. If a full study is implemented, the primary outcome will be to determine if
      nutritional supplementation with omega-3 fatty acids during the last trimester of a mother's
      pregnancy and/or the first three years of life for children who are at higher risk of T1D
      will prevent the development of islet autoimmunity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are two possible entry pathways for study participants. The first pathway is the entry
      point for pregnant mothers in their third trimester (24 weeks gestational age) whose babies
      may be at higher risk for T1D based on family history. At birth, or soon after, their babies
      will be tested for HLA type (to look for the specific gene which confers a higher risk of
      developing T1D). If the HLA typing shows that the baby is at higher risk for T1D and no
      protective genes are present, the baby will then continue in the study. The second pathway is
      the entry point for babies whose mothers were not enrolled during pregnancy. These babies
      will also be tested for HLA type. Their eligibility will be based on the presence of higher
      risk genes or the presence of a multiplex family history. This screening process may take
      place up until the baby is 5 months old.

      Eligible participants (pregnant women or infants) will be randomized to one of the two study
      groups: DHA (docosahexaenoic acid) study substance (this is the intervention) or control
      study substance (this is the placebo). The DHA (docosahexaenoic acid) to be used in this
      trial is produced from algae, not from fish oil, so there is no risk of mercury or pesticide
      contamination.

      Pregnant and nursing mothers who are assigned to the control group will receive study
      capsules containing a vegetable oil and no DHA (docosahexaenoic acid) . Pregnant and nursing
      mothers who are assigned to the experimental group will receive study capsules containing DHA
      (docosahexaenoic acid) . During pregnancy and while breastfeeding, infants will receive the
      study substance indirectly through their mother (either the placenta or breastmilk).

      Infants who are either partially or exclusively formula feeding will receive study substance
      more directly through the study formula. The control group will receive study formula
      containing the typical amount of DHA that can be found in some infant formulas, while infants
      in the experimental group will receive study formula containing a larger amount of DHA
      (docosahexaenoic acid) than typically found in some infant formulas. By six to twelve months
      of age, all infants will get study supplement added to solid foods.

      All mothers will have contact with the study site every 3 months. Nursing mothers will
      provide samples of breast milk for fatty acids analysis at these visits.

      Infants will need to come to follow-up study visits every 6 months. At each of these visits,
      the infant will have a limited physical exam and blood drawn from a vein to monitor immune
      activity, levels of fatty acid and vitamin D, and to check for diabetes-related
      autoantibodies. Infants/children cannot continue in the study if they: (1) develop two
      positive autoantibodies, present at two consecutive visits, or (2) develop T1D.

      All follow-up study visits will continue for 1-2 years, and possibly an additional 2 years if
      a full-scale study is initiated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>20% higher level of plasma and/or red blood cell membrane phospholipid DHA achieved in the treatment group</measure>
    <time_frame>Every 3 months for two years; every 6 months until age 3.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>At least a 20% reduction in the level of the major inflammatory cytokine, IL1-beta, achieved in the plasma of the treatment group</measure>
    <time_frame>Every 3 months for two years; every 6 months until age 3.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>95% of families will continue to attend follow-up visits</measure>
    <time_frame>Every 3 months for two years; every 6 months until age 3.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>DHA Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DHA study treatment given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food)depending on age of child.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for DHA given to nursing mother (breast milk), study formula, or capsules (removing content and mixing with food)depending on age of child.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>DHA Treatment</intervention_name>
    <description>DHA study treatment given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food) depending on age of child.</description>
    <arm_group_label>DHA Treatment Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo for DHA</intervention_name>
    <description>Study placebo given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food)depending on age of child.</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Pregnant mothers are eligible for enrollment into this study if they:

          1. Have T1D or the child's father, or a full or half-sibling of the child has T1D

          2. Are 18 years of age or older

          3. Are in their third trimester of pregnancy (i.e. gestation is 24 weeks or longer)

          4. Have understood and signed a written informed consent and HIPAA authorization

          5. Are willing to undergo randomization to ensure that equal numbers receive the DHA
             study substance versus the control

        Infants are eligible for enrollment into this study if they:

          1. Are less than or equal to six months of age on the date of randomization

          2. Are found to be at risk for type 1 diabetes because they have a mother, father or full
             or half-sibling with T1D AND

               -  have a DR3 or DR4 allele OR

               -  have another relative (includes both 1st and 2nd degree relatives) with T1D
                  (multiplex family)

          3. Have a parent or legal guardian who has understood and signed a written informed
             consent and HIPAA authorization

          4. Have a parent(s) or legal guardian(s) who are willing for their baby to undergo
             randomization to ensure that equal numbers receive the DHA study substance versus the
             control

        Exclusion Criteria

        Pregnant mothers are NOT eligible for enrollment into this study if they:

          1. Have any condition the investigator believes will put the mother or her fetus at an
             unacceptable medical risk for participation in this study

          2. Have a known complication of pregnancy causing an increased risk for the mother or
             fetus prior to entry into the study

          3. Have previously had multiple (2 or more) pre-term births (&lt;36 weeks)

          4. Are diabetic and have a known HbA1c greater than 9% at anytime during the pregnancy
             (however, healthy infants after birth may qualify in spite of the above restrictions
             during pregnancy)

          5. Plan to take DHA supplementation during the study

        Infants are NOT eligible for enrollment into this study if they:

          1. Have any condition the investigator believes will put the subject at an unacceptable
             medical risk for participation in this study

          2. Have a mother with a condition the investigator believes will put her at an
             unacceptable medical risk for participation in this study

          3. Have a nursing mother who plans to take DHA supplementation or has a parent or legal
             guardian who plans to provide supplementation to his/her infant independently during
             the study

          4. Have a protective allele (DQB1*0602 or DRB1*0403)

          5. Were born prior to 36 weeks gestation and require a pre-term infant formula
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>5 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay S Skyler, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_official>
    <last_name>H. Peter Chase, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Colorado Health Science Center- Barbara Davis Center for Childhood Diabetes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Clare-Salzler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida, Department of Pathology, Department of Pediatrics, Diabetes Research Program</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Childrens Hospital of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868-3835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University-Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Health Care</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108-9898</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Diabetes Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.diabetestrialnet.org/</url>
  </link>
  <link>
    <url>http://diabetes.niddk.nih.gov/</url>
  </link>
  <link>
    <url>http://diabetes.niddk.nih.gov/about/index.htm</url>
  </link>
  <link>
    <url>http://www.jdrf.org/</url>
  </link>
  <reference>
    <citation>Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson RA, Chase HP, Eisenbarth GS. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes. 1996 Jul;45(7):926-33.</citation>
    <PMID>8666144</PMID>
  </reference>
  <reference>
    <citation>Karvonen M, Pitk√§niemi J, Tuomilehto J. The onset age of type 1 diabetes in Finnish children has become younger. The Finnish Childhood Diabetes Registry Group. Diabetes Care. 1999 Jul;22(7):1066-70.</citation>
    <PMID>10388969</PMID>
  </reference>
  <reference>
    <citation>Rice R. Fish and healthy pregnancy: more than just a red herring! Prof Care Mother Child. 1996;6(6):171-3. Review.</citation>
    <PMID>9077255</PMID>
  </reference>
  <reference>
    <citation>Stene LC, Joner G; Norwegian Childhood Diabetes Study Group. Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: a large, population-based, case-control study. Am J Clin Nutr. 2003 Dec;78(6):1128-34.</citation>
    <PMID>14668274</PMID>
  </reference>
  <reference>
    <citation>Endres S, Ghorbani R, Kelley VE, Georgilis K, Lonnemann G, van der Meer JW, Cannon JG, Rogers TS, Klempner MS, Weber PC, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med. 1989 Feb 2;320(5):265-71.</citation>
    <PMID>2783477</PMID>
  </reference>
  <reference>
    <citation>Simopoulos AP. Essential fatty acids in health and chronic disease. Am J Clin Nutr. 1999 Sep;70(3 Suppl):560S-569S. doi: 10.1093/ajcn/70.3.560s. Review.</citation>
    <PMID>10479232</PMID>
  </reference>
  <reference>
    <citation>Chase HP, Cooper S, Osberg I, Stene LC, Barriga K, Norris J, Eisenbarth GS, Rewers M. Elevated C-reactive protein levels in the development of type 1 diabetes. Diabetes. 2004 Oct;53(10):2569-73.</citation>
    <PMID>15448085</PMID>
  </reference>
  <reference>
    <citation>Friedberg CE, Janssen MJ, Heine RJ, Grobbee DE. Fish oil and glycemic control in diabetes. A meta-analysis. Diabetes Care. 1998 Apr;21(4):494-500.</citation>
    <PMID>9571330</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2006</study_first_submitted>
  <study_first_submitted_qc>June 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2006</study_first_posted>
  <last_update_submitted>May 13, 2016</last_update_submitted>
  <last_update_submitted_qc>May 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DHA</keyword>
  <keyword>docosahexaenoic acid</keyword>
  <keyword>omega-3 fatty acid</keyword>
  <keyword>fish oil</keyword>
  <keyword>pregnancy</keyword>
  <keyword>infancy</keyword>
  <keyword>prevention</keyword>
  <keyword>&quot;at risk&quot; for developing type 1 diabetes</keyword>
  <keyword>juvenile diabetes</keyword>
  <keyword>T1D</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>Type 1 diabetes TrialNet</keyword>
  <keyword>TrialNet</keyword>
  <keyword>dietary supplementation</keyword>
  <keyword>nutrition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

